The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
The International Ataxia Research Conference will be a comprehensive scientific review of new research into ataxias, covering topics from the molecular basis of disease to potential therapeutic treatments and clinical trials. The conference will include Friedreich’s ataxia and other recessive ataxias (e.g. ataxia with oculomotor apraxia), dominant ataxias (e.g. spinocerebellar ataxias, DRPLA, episodic ataxias) and autoimmune ataxias. The meeting is aimed at academic, clinical and industry researchers with an interest in ataxia research and drug development.
The Huntington Study Group’s renowned annual event, HSG 2019: Navigating HD, will bring together more than 600 of the world’s leading Huntington disease (HD) researchers, health care providers, industry representatives, and members of the HD community to provide a forum for training and education in Huntington disease (HD) and for presentation of new research findings and treatments to the worldwide community,
CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Our mission is to have a positive impact on the success of clinical development programs. We believe this mission is our ethical duty to the patients we serve by developing new treatments.
The conference, now in its 11th year, features leading speakers from the healthcare and investment communities, who will provide insight into future trends in the healthcare industry.
The audience consists of senior management from private and public companies across Europe’s life-sciences sector, as well as a number of investors and analysts from the investment community.
The goal of the CTAD Asia -China Conference is to bring together Asian leaders on the treatment and management of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues that are essential to the development of the next generation of Alzheimer’s disease treatments.
This CTAD Asia - China Conference will focus largely on how to develop successful AD clinical trials worldwide through workshops on important topics for conducting clinical trials: methodology, database management of clinical trials, biomarkers, patient recruitment, etc.
The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field's clinicians, researchers, trainees and industry supporters with an interest in the current research and approaches for the diagnosis and treatment of movement disorders on an annual basis at its International Congress of Parkinson's Disease and Movement Disorders®. The purpose of the MDS International Congress is to share ideas, encourage interest among all those involved in the care and research of movement disorders, to participate in the activities of MDS, and to advance the related clinical and scientific discipline.
The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. It convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer’s disease.
Bringing a drug to market is an arduous task, with the process taking from between 10 to 15 years while costing billions. Therefore, with claims that AI will be able to transform this process by improving the efficiency and optimization of clinical trials, it is no surprise that it has generated intrigue across life science industries. This course will, through the investigation of key use cases, provide understanding on these questions and help management level staff make informed decisions regarding its use in their business.
The EPAD project will host its annual General Assembly meeting in Geneva. The event will bring together EPAD delegates to discuss progress, latest developments and future plans. In attendance will be scientists, researchers, representatives from pharmaceutical companies, patient organisations, SMEs, EPAD study site members, other experts and research participants from across many different countries.
1-10 of 17 results